By PPN News Staff
The FDA approved tirzepatide (Mounjaro, Eli Lilly) as an adjunct therapy to diet and exercise for improving glycemic control in adults with type 2 diabetes.
Tirzepatide, an injectable glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide agonist, was more effective than other diabetes therapies compared in clinical studies, the FDA said.
“Given the challenges many patients experience in achieving their target blood sugar goals, today’s